Research Analysts Offer Predictions for GSK Q3 Earnings

GSK PLC Sponsored ADR (NYSE:GSK) – Equities researchers at Zacks Research cut their Q3 2025 earnings estimates for shares of GSK in a research report issued on Tuesday, August 19th. Zacks Research analyst Team now expects that the pharmaceutical company will earn $1.23 per share for the quarter, down from their prior estimate of $1.29. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.79 EPS, FY2025 earnings at $4.39 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.21 EPS, Q3 2026 earnings at $1.33 EPS, Q1 2027 earnings at $1.16 EPS, Q2 2027 earnings at $1.21 EPS and FY2027 earnings at $4.75 EPS.

A number of other equities analysts have also commented on the stock. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Sunday, August 3rd. Berenberg Bank reiterated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a research note on Monday, April 28th. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Reduce” and a consensus target price of $37.38.

GSK Stock Performance

Shares of GSK stock opened at $40.1450 on Friday. GSK has a 12 month low of $31.72 and a 12 month high of $44.67. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a market capitalization of $81.80 billion, a P/E ratio of 18.59, a P/E/G ratio of 1.74 and a beta of 0.51. The company’s fifty day moving average price is $38.34 and its two-hundred day moving average price is $38.11.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same period in the prior year, the company earned $0.43 EPS. The firm’s revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, August 15th. GSK’s dividend payout ratio is currently 77.78%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC bought a new position in GSK in the 4th quarter worth about $528,000. First Hawaiian Bank grew its position in GSK by 18.8% in the 1st quarter. First Hawaiian Bank now owns 101,039 shares of the pharmaceutical company’s stock worth $3,914,000 after purchasing an additional 15,987 shares during the last quarter. Barclays PLC grew its position in GSK by 84.2% in the 4th quarter. Barclays PLC now owns 49,628 shares of the pharmaceutical company’s stock worth $1,678,000 after purchasing an additional 22,689 shares during the last quarter. Crestline Management LP bought a new position in GSK in the 4th quarter worth about $1,047,000. Finally, Stifel Financial Corp grew its position in GSK by 2.2% in the 4th quarter. Stifel Financial Corp now owns 618,213 shares of the pharmaceutical company’s stock worth $20,908,000 after purchasing an additional 13,240 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.